Skip to main content
Atrás
Watch Compare

Upstream Bio, Inc.

Calidad de datos: 100%
UPB
NASDAQ Manufacturing Chemicals
$10.34
▲ $0.11 (1.08%)
6 months return
—
Momentum
Neutral
ROE
-36.44%

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)20.42%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-36.44%
Above sector avg (-54.49%)
ROIC-32.12%
Net Margin-5026.03%
Op. Margin-5618.82%

Seguridad

Debt / Equity
N/A
Current Ratio32.67
Interest CoverageN/A

Valoración

PE (TTM|NTM)
-3.98 | -3.25
Below sector avg (-1.50)
P/B Ratio1.51
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -133.44 M
Capital efficient — spends only 5.78% of revenue on capex

Price History

Tendencias Financieras

Precio Objetivo de Analistas

7 analistas
Buy
+321.4%
upside to target
Actual
$10.34
Consensus Target
$43.57
$15.00
Mín
$75.00
Máx
Pronóstico
P/E Futuro
-3.25
EPS Futuro
-$3.23
Ingresos Est.
1.22 M

Sorpresas de Ganancias

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -$0.75 · Rev Est: 347,170.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -$0.51 -$0.74 -$0.63 -$0.78 — —
Estimate -$0.48 -$0.61 -$0.78 -$0.70 -$0.75 -$0.74
Sorpresa -5.21% -21.24% +19.52% -11.58% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) 20.42% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -36.44% · Net Margin: -5026.03%
Revenue (TTM) 2.85 M Net Income (TTM) -143.44 M
ROE -36.44% ROA -35.34%
Gross Margin N/A Operating Margin -5618.82%
Net Margin -5026.03% Free Cash Flow (TTM) -133.44 M
ROIC -32.12% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 32.67
Debt / Equity N/A Current Ratio 32.67
Interest Coverage N/A Asset Turnover 0.01
Working Capital 377.11 M Tangible Book Value 378.58 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -3.98 · EV/EBITDA: N/A
P/E Ratio -3.98 Forward P/E -3.25
P/B Ratio 1.51 P/S Ratio 200.02
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 469.57 Fwd Earnings Yield N/A
FCF Yield -23.38%
Market Cap 570.87 M Enterprise Value 498.70 M

Per Share

EPS: -2.66 · FCF/Share: -2.45
EPS (Diluted TTM) -2.66 Revenue / Share 0.05
FCF / Share -2.45 OCF / Share -2.45
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 93.03% · CapEx/Rev: 5.78%
CapEx / Revenue 5.78% FCF Conversion 93.03%
SBC-Adj. FCF -145.18 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 2.85 M 2.37 M
Net Income -143.44 M -62.81 M
EPS (Diluted) -2.66 -5.58
Gross Profit — —
Operating Income -160.36 M -77.76 M
EBITDA — —
R&D Expenses 136.81 M 62.97 M
SG&A Expenses — —
D&A 188,000.0 89,000.0
Interest Expense — —
Income Tax 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 353.77 M 481.72 M
Total Liabilities 14.00 M 11.87 M
Shareholders' Equity 339.77 M 469.85 M
Total Debt — —
Cash & Equivalents 101.58 M 325.89 M
Current Assets 351.80 M 479.16 M
Current Liabilities 13.45 M 10.74 M

Comparación con Pares

vs mediana del sector Manufacturing (1605 pares)
Métrica Acción Mediana del Sector
P/E -4.0 -1.5
P/B 1.5 1.6
ROE % -36.4 -54.5
Net Margin % -5026.0 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock
BBC logo BBC Virtus Biotech Clinical Trials ETF
1.06% weight
AVSCX AVSCX
0.08% weight
SHSAX SHSAX
0.08% weight
SHSCX SHSCX
0.08% weight
SHISX SHISX
0.08% weight
VVICX VVICX
0.03% weight
IRCIX IRCIX
0.03% weight
IRSIX IRSIX
0.03% weight
IIRSX IIRSX
0.03% weight
IRSSX IRSSX
0.02% weight